Meeting
2021 Genitourinary Cancers Symposium
SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy.
Authors
Andrea Necchi
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrea Necchi , Daniele Raggi , Marco Bandini , Andrea Gallina , Umberto Capitanio , Giorgio Gandaglia , Vito Cucchiara , Nicola Fossati , Francesco De Cobelli , Andrea Salonia , Gromek Smolen , Sohail Balasubramanian , Ewan Gibb , Jeffrey S. Ross , Russell Madison , Alberto Briganti , Stefano Cascinu , Francesco Montorsi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
2020-004844-27
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS506)
DOI
10.1200/JCO.2021.39.6_suppl.TPS506
Abstract #
TPS506
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).
First Author: Guru P. Sonpavde
Poster
2021 ASCO Annual Meeting
Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).
First Author: Ana Christina Garrido-Castro
Poster
2021 ASCO Annual Meeting
Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).
First Author: Ana Christina Garrido-Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC).
First Author: Chiara Mercinelli